{"id":1551,"date":"2026-06-01T21:48:14","date_gmt":"2026-06-02T01:48:14","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1551"},"modified":"2026-06-01T21:49:47","modified_gmt":"2026-06-02T01:49:47","slug":"tune-401-epigenetic-silencing-clinical-poc","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1551","title":{"rendered":"TUNE-401 Epigenetic Silencing Clinical PoC"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Summary<\/h4>

Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients.<\/p>

What Happened<\/h4>

At EASL 2026, Tune reported Phase 1b\/2a data showing epigenetic silencing of HBV cccDNA and integrated viral DNA without DNA cleavage. The study demonstrated favorable safety and tolerability together with durable biomarker suppression. The company plans to initiate Phase 2 development as early as late 2026.<\/p>

Deep Analysis<\/h4>

This is a foundational platform milestone for the entire gene-editing field. Unlike nuclease-based CRISPR approaches that create DNA breaks, Tune’s platform uses programmable transcriptional repression to silence genes without permanent DNA cutting. Successful human proof-of-concept substantially de-risks epigenetic editing and may create a new therapeutic category. The implications extend beyond HBV into hematology, sickle cell disease, beta-thalassemia, AML, ALL, MDS, MPNs and engineered immune-cell therapies.<\/p>

Company \/ Product Background<\/h4>

Tune Therapeutics is developing epigenetic editing medicines that regulate gene expression without changing DNA sequence. TUNE-401 targets HBV cccDNA and integrated viral DNA using CRISPR-based transcriptional silencers.<\/p>

Signal Extraction<\/h4>

– First human proof-of-concept for epigenetic editing
– CRISPR without double-strand DNA breaks validated clinically
– Major safety narrative shift for gene editing field
– Strong platform relevance to hematology and cell therapy<\/p>

Insilens Take<\/h4>

– Opportunity: Potential next-generation alternative to nuclease editing
– Threat: Long-term durability still needs validation
– Watch Signal: First hematology-focused clinical program
– Action: Monitor platform expansion beyond HBV<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Summary Tune Therapeutics presented the first clinical proof-of-concept data for CRISPR-based epigenetic silencing in humans, demonstrating deep, dose-dependent and durable reductions in HBV biomarkers with TUNE-401 in chronic hepatitis B patients. What Happened At EASL 2026, Tune reported Phase 1b\/2a data showing epigenetic silencing of HBV cccDNA and integrated viral DNA without DNA cleavage. The […]<\/p>\n","protected":false},"author":1,"featured_media":1552,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[],"class_list":["post-1551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1551"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1551\/revisions"}],"predecessor-version":[{"id":1556,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1551\/revisions\/1556"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1552"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}